A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
- Mechanism
- Curator reviewed
DHLA (or DGLA) is a precursor in the synthesis of prostaglandin E1 (PGE1) as well as the series-3 prostaglandins. It also serves as a precursor in the synthesis of eicosapentaenoic acid (EPA). EPA is a precursor of the series-3 prostaglandins, the series-5 leukotrienes and the series-3 thromboxanes. These eicosanoids have anti-thrombogenic, anti-inflammatory and anti-atherogenic properties. PGE1 inhibits platelet aggregation and has a vasodilation action. DHLA has also been shown to reduce the production/activity of tumor necrosis factor alpha.
- Primary indication
- For nutritional supplementation, also for treating dietary shortage or imbalanceCurator reviewed
- Formula / weight
- C20H34O2 · 306.4828 g/mol (avg)
- Also known as
- DGLA · Dihomo-gamma-linolenic acid · Diroleuton · gamma-Homolinolenic acid · Homo-gamma-linolenic acid
- Code names
- DS-107G · RO 12-1989
Resolves to
HOBAELRKJCKHQD-QNEBEIHSSA-NSMILESCCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Daleuton, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account